It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Changes in legislation have affected supply routes of new psychoactive substances such as synthetic cannabinoids with evidence of supply over the darknet. We identified darknet drug markets using an index database and Tor Browser to access markets. We identified SC in product listings using a custom-programmed script. We collected data at bimonthly intervals (August 2016–April 2017). Eleven darknet markets listed SC for sale, the largest number from China, UK, US, Netherlands, and Germany. Formulations available were high purity powder/crystal, smoking preparations and vape preparations. The top five listed compounds from China across the time points were FUB-AMB, ABD-FUBINACA, 5F-NPB-22, MAB-CHMINACA, and NM-2201. 5F-CUMYL-4CN-PINACA was unavailable at early time points but emerged during the study. Cost of high purity formulations from China ranged from 1.3 to 3.1 Euro per gram for quantities ≥1000 g. Europe and North America accounted for 99% smoking preparations predominantly in small packages (<50 g). SC are widely available on the darknet with availability changing over time. High purity formulations are predominantly available from China in quantities up to kilograms with price per gram reducing with increased quantity. Small packages of ready-made smoking mixtures are available from Europe and North America.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details



1 Clinical Toxicology, Guys and St Thomas’ NHS Foundation Trust, London, UK;
2 Centre for Computing and Social Responsibility, De Montfort University, Leicester, UK;
3 Clinical Toxicology, Guys and St Thomas’ NHS Foundation Trust, London, UK;; Faculty of Life Sciences and Medicine, King’s College London, London, UK;
4 Emergency Medicine and Clinical Toxicology, Prince of Wales Hospital, Sydney, NSW, Australia;
5 The Marie Bashir Institute for Infectious Diseases and Biosecurity, The University of Sydney, Sydney, NSW, Australia;; Médecins Sans Frontières—UK, London, UK